Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Spanish Oncology Genitourinary Group"'
Autor:
Conteduca, Vincenza, Wetterskog, Daniel, Sharabiani, Grande, Enrique, Fernandez Perez, M. P., Jayaram, Anuradha, Salvi, S., Castellano, Daniel, Romanel, A., Lolli, C., Casadio, Valentina, Gurioli, G., Amadori, D., Font, A., Vazquez Estevez, S., González del Alba, A., Mellado, B., Fernandez Calvo, O., Méndez Vidal, M. J., Climent, M. A., Durán, I, Gallardo, E., Rodríguez Sánchez, Ángel, Santander, C., Sáez, M. I., Puente, J., Gasi Tandefelt, D., Wingate, Anna, Dearnaley, D., Demichelis, F., De Giorgi, Ugo, Gonzalez Billalabeitia, E., Attard, Gerhardt, Spanish Oncology Genitourinary Group, Universitat Autònoma de Barcelona
Publikováno v:
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Universitat Autònoma de Barcelona
Background: There is an urgent need to identify biomarkers to guide personalized therapy in castration-resistant prostate cancer (CRPC). We aimed to clinically qualify androgen receptor (AR) gene status measurement in plasma DNA using multiplex dropl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::3f7a13e508cd658a892e3a732492dab6
https://hdl.handle.net/20.500.13003/9759
https://hdl.handle.net/20.500.13003/9759
Autor:
González-Billalabeitia E, Sepúlveda JM, Maroto P, Aparicio J, Arranz JA, Esteban E, Gironés R, López-Brea M, Mendez-Vidal MJ, Pinto A, Sastre J, de Prado DS, Terrasa J, Vázquez S, Powles T, Beyer J, Castellano D, Del Muro XG, Spanish Germ Cell Cancer Group and the Spanish Oncology Genitourinary Group
Publikováno v:
European Urology Focus
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
BACKGROUND: High-dose chemotherapy (HDCT) has been studied in several clinical scenarios in advanced germ cell cancer (GCC). OBJECTIVE: To establish a clinical practice guideline for HDCT use in the treatment of GCC patients. DESIGN, SETTING, AND PAR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::6f2b168b083d175548d0636d2bf8c461
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=6282
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=6282
Autor:
Conteduca, V., Wetterskog, D., Sharabiani, M. T. A., Grande, Enrique, Fernández-Pérez, M. P., Jayaram, A., Castellano-Castillo, Daniel, Romanel, A., Lolli, C., Casadio, V., Gurioli, G., Amadori, D., Font, A., Vázquez-Estévez, S., González del Alba, Aránzazu, Mellado, B., Fernández-Calvo, O., Méndez-Vidal, M. J., Climent, M. A., Durán, Ignacio, Gallardo, Eduard, Rodríguez, A., Santander, C., Sáez, María Isabel, Puente, Javier, Gasi Tandefelt, D., Wingate, A., Dearnaley, D., Demichelis, F., de Giorgi, U., González-Billalabeitia, E., Attard, G.
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
instname
[Background] There is an urgent need to identify biomarkers to guide personalized therapy in castration-resistant prostate cancer (CRPC). We aimed to clinically qualify androgen receptor (AR) gene status measurement in plasma DNA using multiplex drop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::793843c3bb6b5afa1337a9dc3f58e1a1
http://hdl.handle.net/10261/182664
http://hdl.handle.net/10261/182664
Autor:
Verbiest A; Department of General Medical Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.; Department of Oncology, Laboratory of Experimental Oncology, KU Leuven, Leuven, Belgium., Van Hoef V; Bioinformatics Expertise Center, VIB, Leuven, Belgium., Rodriguez-Antona C; Hereditary Endocrine Cancer Group, Human Cancer Genetics Programme, Spanish National Cancer Research Centre, Madrid, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain., García-Donas J; Oncology Unit, HM Hospitales-Centro Integral Oncologico HM Clara Campal, Madrid, Spain.; Spanish Oncology Genitourinary Group, Madrid, Spain., Graña-Castro O; Bioinformatics Unit, Structural Biology and Biocomputing Programme, Spanish National Cancer Research Centre, Madrid, Spain., Albersen M; Department of Urology, University Hospitals Leuven, Leuven, Belgium., Baldewijns M; Department of Imaging and Pathology, KU Leuven, Leuven, Belgium., Laenen A; Biostatistics and Statistical Bioinformatics Center, KU Leuven, Leuven, Belgium., Roussel E; Department of Urology, University Hospitals Leuven, Leuven, Belgium., Schöffski P; Department of General Medical Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.; Department of Oncology, Laboratory of Experimental Oncology, KU Leuven, Leuven, Belgium., Wozniak A; Department of General Medical Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.; Department of Oncology, Laboratory of Experimental Oncology, KU Leuven, Leuven, Belgium., Caruso S; Inserm, UMR-1162, Génomique fonctionnelle des tumeurs solides, IUH, Paris, France., Couchy G; Inserm, UMR-1162, Génomique fonctionnelle des tumeurs solides, IUH, Paris, France., Zucman-Rossi J; Inserm, UMR-1162, Génomique fonctionnelle des tumeurs solides, IUH, Paris, France., Beuselinck B; Department of General Medical Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.; Department of Oncology, Laboratory of Experimental Oncology, KU Leuven, Leuven, Belgium.
Publikováno v:
PloS one [PLoS One] 2020 Sep 11; Vol. 15 (9), pp. e0238809. Date of Electronic Publication: 2020 Sep 11 (Print Publication: 2020).
Autor:
Roldan-Romero JM; Hereditary Endocrine Cancer Group, Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Rodríguez-Moreno JF; Genitourinary and Gynecological Cancer Unit, Clara Campal Comprehensive Cancer Center, Madrid, Spain.; Spanish Oncology GenitoUrinary Group (SOGUG), Spain., García-Donás J; Genitourinary and Gynecological Cancer Unit, Clara Campal Comprehensive Cancer Center, Madrid, Spain. crodriguez@cnio.es jgarciadonas@gmail.com.; Spanish Oncology GenitoUrinary Group (SOGUG), Spain., Rodríguez-Antona C; Hereditary Endocrine Cancer Group, Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. crodriguez@cnio.es jgarciadonas@gmail.com.; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2017 Sep 01; Vol. 23 (17), pp. 5320.
Autor:
Liu X; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.; Institute of Clinical Pharmacology, Qilu Hospital of Shandong University, Jinan, China., Swen JJ; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, Netherlands., Boven E; Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands., Castellano D; Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.; Spanish Oncology Genitourinary Group (SOGUG), Madrid, Spain., Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Mathijssen RH; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Rodríguez-Antona C; Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.; ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Madrid, Spain., García-Donas J; Spanish Oncology Genitourinary Group (SOGUG), Madrid, Spain.; Oncology Unit, Clara Campal Comprehensive Cancer Center, Madrid, Spain., Rini BI; Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute (CCF), Cleveland, Ohio, USA., Guchelaar HJ; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.
Publikováno v:
Oncotarget [Oncotarget] 2017 Jan 03; Vol. 8 (1), pp. 1204-1212.
Autor:
Diekstra MH; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.; Dutch Working Group Focusing on Genotype-related Sunitinib-induced Toxicity (SUTOX Consortium), Leiden, The Netherlands., Belaustegui A; Department of Clinical Pharmacy, Hospital Universitario Cruces, Barakaldo, Bizkaia, Spain., Swen JJ; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.; Dutch Working Group Focusing on Genotype-related Sunitinib-induced Toxicity (SUTOX Consortium), Leiden, The Netherlands., Boven E; Dutch Working Group Focusing on Genotype-related Sunitinib-induced Toxicity (SUTOX Consortium), Leiden, The Netherlands.; Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands., Castellano D; Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.; Spanish Oncology Genitourinary Group, Madrid, Spain., Gelderblom H; Dutch Working Group Focusing on Genotype-related Sunitinib-induced Toxicity (SUTOX Consortium), Leiden, The Netherlands.; Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Mathijssen RH; Dutch Working Group Focusing on Genotype-related Sunitinib-induced Toxicity (SUTOX Consortium), Leiden, The Netherlands.; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., García-Donas J; Spanish Oncology Genitourinary Group, Madrid, Spain.; Oncology Unit, Clara Campal Comprehensive Cancer Center, Madrid, Spain., Rodríguez-Antona C; Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center, Madrid, Spain.; ISCIII Center for Biomedical Research on Rare Diseases, Madrid, Spain., Rini BI; Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA., Guchelaar HJ; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.; Dutch Working Group Focusing on Genotype-related Sunitinib-induced Toxicity (SUTOX Consortium), Leiden, The Netherlands.
Publikováno v:
The pharmacogenomics journal [Pharmacogenomics J] 2017 Jan; Vol. 17 (1), pp. 42-46. Date of Electronic Publication: 2016 Jan 26.
Autor:
García-Donas J; Oncology Unit, HM Hospitales - Centro Integral Oncológico HM Clara Campal, Madrid, Spain.; Spanish Oncology Genitourinary Group, Madrid, Spain., Beuselinck B; Department of General Medical Oncology, University Hospitals Leuven, and.; Laboratory for Experimental Oncology, KU Leuven, Leuven, Belgium., Inglada-Pérez L; Hereditary Endocrine Cancer Group, Human Cancer Genetics Programme, Spanish National Cancer Research Centre, Madrid, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain., Graña O; Bioinformatics Unit, Structural Biology and Biocomputing Programme, Spanish National Cancer Research Centre, Madrid, Spain., Schöffski P; Department of General Medical Oncology, University Hospitals Leuven, and.; Laboratory for Experimental Oncology, KU Leuven, Leuven, Belgium., Wozniak A; Laboratory for Experimental Oncology, KU Leuven, Leuven, Belgium., Bechter O; Department of General Medical Oncology, University Hospitals Leuven, and.; Laboratory for Experimental Oncology, KU Leuven, Leuven, Belgium., Apellániz-Ruiz M; Hereditary Endocrine Cancer Group, Human Cancer Genetics Programme, Spanish National Cancer Research Centre, Madrid, Spain., Leandro-García LJ; Hereditary Endocrine Cancer Group, Human Cancer Genetics Programme, Spanish National Cancer Research Centre, Madrid, Spain., Esteban E; Spanish Oncology Genitourinary Group, Madrid, Spain.; Hospital Universitario Central de Asturias, Oviedo, Spain., Castellano DE; Spanish Oncology Genitourinary Group, Madrid, Spain.; Hospital Universitario 12 de Octubre, Madrid, Spain., González Del Alba A; Spanish Oncology Genitourinary Group, Madrid, Spain.; Hospital Universitario Son Espases, Palma de Mallorca, Spain., Climent MA; Spanish Oncology Genitourinary Group, Madrid, Spain.; Fundación Instituto Valenciano de Oncología, Valencia, Spain., Hernando S; Spanish Oncology Genitourinary Group, Madrid, Spain.; Hospital Universitario Fundación Alcorcón, Madrid, Spain., Arranz JA; Spanish Oncology Genitourinary Group, Madrid, Spain.; Hospital General Universitario Gregorio Marañón, Madrid, Spain., Morente M; Tumour Bank Unit, Spanish National Cancer Research Centre, Madrid, Spain., Pisano DG; Bioinformatics Unit, Structural Biology and Biocomputing Programme, Spanish National Cancer Research Centre, Madrid, Spain., Robledo M; Hereditary Endocrine Cancer Group, Human Cancer Genetics Programme, Spanish National Cancer Research Centre, Madrid, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain., Rodriguez-Antona C; Hereditary Endocrine Cancer Group, Human Cancer Genetics Programme, Spanish National Cancer Research Centre, Madrid, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain.
Publikováno v:
JCI insight [JCI Insight] 2016 Jul 07; Vol. 1 (10), pp. e86051. Date of Electronic Publication: 2016 Jul 07.
Autor:
Duran I; Hospital Universitario Virgen del Rocio, Seville, Spain., Hagen C; Spanish Oncology Genitourinary Group, Madrid, Spain., Arranz JÁ; Hospital Universitario Gregorio Marañon. Madrid, Spain., Apellaniz-Ruiz M; Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Pérez-Valderrama B; Hospital Universitario Virgen del Rocio, Seville, Spain., Sala N; Instituto Catalan de Oncologia Josep Trueta, Girona, Spain., Lainez N; Complejo Hospitalario de Navarra, Pamplona, Spain., García-Del Muro X; Instituto Catalan de Oncologia, L'Hospitalet, Spain., Noguerón E; Complejo Hospitalario Universitario de Albacete, Albacete, Spain., Climent MÁ; Instituto Valenciano de Oncologia, Valencia, Spain., Maroto P; Hospital de la Santa Creu y Sant Pau, Barcelona, Spain., Font A; Instituto Catala de Oncologia, Hospital Universitario Germans Trias y Pujol, Badalona, Spain., García-Donas J; Centro Integral Oncologico Clara Campal, Madrid, Spain., Gallardo E; Corporacio Sanitaria Parc Tauli, Sabadell, Spain., López-Criado P; MD Anderson Madrid, Madrid, Spain., González Del Alba A; Hospital Universitario Son Espases, Palma de Mallorca, Spain., Sáez MI; Hospital Universitario Virgen de la Victoria, Malaga, Spain., Vázquez S; Hospital Lucus Augusti, Lugo, Spain., Luque R; Hospital Universitario Virgen de las Nieves, Granada, Spain., Rodríguez-Antona C; Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.; ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Madrid, Spain.
Publikováno v:
Pharmacogenomics [Pharmacogenomics] 2016 Apr; Vol. 17 (5), pp. 463-71. Date of Electronic Publication: 2016 Mar 29.
Autor:
Diekstra MH; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Albinusdreef 2, Leiden, 2333ZA, Netherlands.; Dutch SUTOX consortium, Leiden, Netherlands., Liu X; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Albinusdreef 2, Leiden, 2333ZA, Netherlands.; Dutch SUTOX consortium, Leiden, Netherlands.; Institute of Clinical Pharmacology, Qilu Hospital of Shandong University, Jinan, China., Swen JJ; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Albinusdreef 2, Leiden, 2333ZA, Netherlands. j.j.swen@lumc.nl.; Dutch SUTOX consortium, Leiden, Netherlands. j.j.swen@lumc.nl., Boven E; Dutch SUTOX consortium, Leiden, Netherlands.; Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands., Castellano D; Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.; Spanish Oncology Genitourinary Group (SOGUG), Madrid, Spain., Gelderblom H; Dutch SUTOX consortium, Leiden, Netherlands.; Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands., Mathijssen RH; Dutch SUTOX consortium, Leiden, Netherlands.; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands., Rodríguez-Antona C; Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.; ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Madrid, Spain., García-Donas J; Spanish Oncology Genitourinary Group (SOGUG), Madrid, Spain.; Oncology Unit, Clara Campal Comprehensive Cancer Center, Madrid, Spain., Rini BI; Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute (CCF), Cleveland, OH, USA., Guchelaar HJ; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Albinusdreef 2, Leiden, 2333ZA, Netherlands.; Dutch SUTOX consortium, Leiden, Netherlands.
Publikováno v:
European journal of clinical pharmacology [Eur J Clin Pharmacol] 2015 Dec; Vol. 71 (12), pp. 1477-84. Date of Electronic Publication: 2015 Sep 21.